Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of data fro
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … quantitative sciences and a passion for innovation in drugdevelopment. Location: Leiden, NL Key Responsibilities: …
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … and external partners, focused on the development of novel drug candidates for the treatment of chronic liver diseases. … of research efforts, driving innovation and efficiency in drugdevelopment. Proactively identify complex obstacles to …
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … skills to integrate biomarker science into all stages of drugdevelopment. Key Responsibilities: Strategic Leadership …
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … Design, conduct and interpret these models to support drug screening and target validation, and to generate … and literature. Broad interest in different areas of drugdevelopment areas, such as molecular/cellular processes, …